Dublin, July 31, 2024 (GLOBE NEWSWIRE) -- The "Fragile X Syndrome - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.
This report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Fragile X Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
"Fragile X Syndrome - Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Fragile X Syndrome pipeline landscape is provided which includes the disease overview and Fragile X Syndrome treatment guidelines.
The assessment part of the report embraces, in depth Fragile X Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Fragile X Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Fragile X Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Fragile X Syndrome
Major Players in Fragile X Syndrome
There are approx. 10+ key companies which are developing the therapies for Fragile X Syndrome. The companies which have their Fragile X Syndrome drug candidates in the most advanced stage, i.e. Phase III include, Zynerba Pharmaceuticals, Inc.
Fragile X Syndrome Emerging Drugs Chapters
This segment of the Fragile X Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Fragile X Syndrome Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Fragile X Syndrome therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Fragile X Syndrome drugs.
Fragile X Syndrome Emerging Drugs
ZYN002: Zynerba Pharmaceuticals, Inc.
Zynerba's ZYN002 CBD Gel is the first and only synthetic CBD formulated as a patent-protected permeation-enhanced gel and is being studied in refractory epilepsy, Fragile X syndrome and osteoarthritis. It is a clear, permeation-enhanced gel that is designed to provide consistent, controlled drug delivery transdermally with convenient once- or twice-daily dosing. Currently, the drug is in Phase III stage of its clinical trial for the treatment of fragile x syndrome.
NNZ-2566: Neurons Pharmaceuticals Limited
NNZ-2566 is a synthetic analogue of a naturally occurring molecule produced by the brain in response to injury. That molecule, a small part of the insulin-like growth factor-1 (IGF-1) molecule, belongs to a group of molecules called neuropeptides. Currently, the drug is in phase II stage of its clinical trial for the treatment of fragile x syndrome.
Key Questions
- How many companies are developing Fragile X Syndrome drugs?
- How many Fragile X Syndrome drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Fragile X Syndrome?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Fragile X Syndrome therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Fragile X Syndrome and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Zynerba Pharmaceuticals, Inc.
- Tetra Discovery Partners
- Nova Mentis Life Science Corp
- Neuren Pharmaceuticals Limited
- Tetra Discovery Partners
Key Products
- ZYN002
- Zatolmilast
- Psilocybin
- NNZ-2566
- BPN14770
Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Fragile X Syndrome Report Insights
- Fragile X Syndrome Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Fragile X Syndrome Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/ml0sft
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.